MARC SCHNEEBAUM, Chief Executive Officer >>
ANTHONY P. SHUBER, M.S., Chief Technology Officer & Co-Founder >>
ANGELO M. DE MARZO, M.D., Ph.D., Chief Medical Officer >>
THOMAS ROSS, Chief Commercial Officer >>
ANDY HU, MD, Vice President, Strategy >>
MARC SCHNEEBAUM
Chief Executive Officer
Mr. Schneebaum brings over twenty years of demonstrated success in corporate finance, technology development, business development and general management. Before joining Predictive Biosciences, Marc spent the previous 13 years with Sensors for Medicine and Science, Inc., where he served as President and CEO. During his tenure, he led the company from concept through human clinical studies, successfully grew its valuation from $6 million to more than $90 million, and raised over $56 million in venture capital. Other positions held by Marc include, CFO and Senior Vice President of Finance and Business Development at Genetic Therapy Inc. (GTI), where he completed a successful IPO and three additional public stock offerings, and raised over $100 million dollars prior to participating in the negotiation and implementation of its merger with Sandoz AG (now Novartis). Marc also was a Vice President at Alex Brown & Sons Inc., a leading investment banking firm (now part of Deutsche Bank).
ANTHONY P. SHUBER, M.S.
Chief Technology Officer & Co-Founder
Mr. Shuber leads the company's overall scientific efforts and its applied research team. He has more than two decades of experience in highly successful research, development and commercialization of diagnostics and applied genomics. Most recently, Tony served as Co-Founder, Executive Vice President and Chief Technology Officer for EXACT Sciences, an applied genomics company focused on developing proprietary non-invasive, DNA-based screening tools for the early detection of cancer. At EXACT, Tony spearheaded the development of DNA-based molecular technologies used for commercial cancer screening. Previously, he held key scientific, management roles with Genzyme Genetics / Integrated Genetics, as well as earlier research and management positions. Tony holds more than 30 patents and has authored numerous peer-reviewed papers. He earned his undergraduate and graduate degrees from Marquette University in Milwaukee, Wisconsin.
ANGELO M. DE MARZO, M.D., Ph.D.
Chief Medical Officer
Dr. De Marzo leads the company’s overall medical efforts. Previously, Angelo was a Professor of Pathology, Oncology and Urology and a member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, where he still maintains an adjunct faculty position. He received his undergraduate, medical and graduate degrees from the University of Colorado. He completed a residency in anatomic pathology at The Johns Hopkins University School of Medicine in 1997 and since 1998 he has been a practicing boarded urological pathologist, focusing extensively on prostate pathology. His research at Johns Hopkins focused on the molecular mechanisms involved in cancer initiation and progression, as well as, the role of inflammation in prostate cancer. He also performed clinical diagnostic, prognostic and predictive biomarker research in urological cancers. Angelo has published more than 200 articles, has served on a number of NIH grant review panels, is a former member of the Department of Defense Prostate Cancer Research Program (PCRP) Integration Panel, and currently serves on the Editorial Board for the journals The Prostate and Cancer Prevention Research.
THOMAS ROSS
Chief Commercial Officer
Mr. Ross leads the company’s commercial operations. He brings over 20 years of operational management and direct sales experience with a track record of generating unprecedented revenue in the medical diagnostics industry. Previously, Tom served as Vice President of North American Medical Diagnostics Sales at QIAGEN, where he managed its major product lines and helped establish the company as a leader in infectious disease testing. Previously at Digene, he drove the rapid expansion of both physician and laboratory sales, and led the sales and marketing integration team when the company was acquired by QIAGEN. At Cambrex Corporation, a small molecule therapeutics-based company, he was responsible for the commercial development of the $65 million contract manufacturing business. Tom holds a B.S. in business administration from The Citadel.
ANDY HU, MD
Vice President, Strategy
Dr. Hu leads the company’s strategic and business development activities. Andy was previously in the investment banking group at Leerink Swann, where he executed more than $600 million in equity financings and merger and acquisition transactions for emerging growth diagnostic, biotechnology, specialty pharmaceutical and medical device companies. Previously, he was a Senior Consultant at Strategic Decisions Group, leading consulting assignments for several Fortune 500 healthcare companies developing therapeutic area, portfolio, and licensing and acquisition strategies. Andy received his medical training at Baylor College of Medicine. In addition, he holds an MBA from the Rice University Jones Graduate School of Business, an undergraduate degree from Harvard University, where he was named a Presidential Scholar.
